Posibles problemas de falta de objetividad, transparencia, doble publicación y autoría en el análisis coste-efectividad de celecoxib
Possible problems of lack of objectivity, transparency, duplicate publication and authorship in the cost-effectiveness analysis of celecoxib
Leído
5774
Vecesse ha leído el artículo
1805
Total PDF
3969
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 10 | 6 | 16 |
| 2025 5 | 61 | 19 | 80 |
| 2025 4 | 43 | 22 | 65 |
| 2025 3 | 41 | 23 | 64 |
| 2025 2 | 45 | 23 | 68 |
| 2025 1 | 48 | 14 | 62 |
| 2024 12 | 39 | 18 | 57 |
| 2024 11 | 50 | 35 | 85 |
| 2024 10 | 49 | 31 | 80 |
| 2024 9 | 44 | 20 | 64 |
| 2024 8 | 43 | 26 | 69 |
| 2024 7 | 34 | 21 | 55 |
| 2024 6 | 30 | 18 | 48 |
| 2024 5 | 32 | 18 | 50 |
| 2024 4 | 28 | 13 | 41 |
| 2024 3 | 32 | 24 | 56 |
| 2024 2 | 23 | 42 | 65 |
| 2024 1 | 18 | 17 | 35 |
| 2023 12 | 20 | 16 | 36 |
| 2023 11 | 34 | 11 | 45 |
| 2023 10 | 23 | 12 | 35 |
| 2023 9 | 33 | 19 | 52 |
| 2023 8 | 24 | 7 | 31 |
| 2023 7 | 29 | 26 | 55 |
| 2023 6 | 38 | 16 | 54 |
| 2023 5 | 29 | 6 | 35 |
| 2023 4 | 30 | 17 | 47 |
| 2023 3 | 34 | 36 | 70 |
| 2023 2 | 23 | 19 | 42 |
| 2022 1 | 21 | 21 | 42 |
| 2022 12 | 28 | 27 | 55 |
| 2022 11 | 32 | 39 | 71 |
| 2022 10 | 33 | 29 | 62 |
| 2022 9 | 23 | 32 | 55 |
| 2022 8 | 30 | 47 | 77 |
| 2022 7 | 32 | 44 | 76 |
| 2022 6 | 24 | 37 | 61 |
| 2022 5 | 25 | 26 | 51 |
| 2022 4 | 30 | 31 | 61 |
| 2022 3 | 20 | 37 | 57 |
| 2022 2 | 24 | 32 | 56 |
| 2021 1 | 22 | 41 | 63 |
| 2021 12 | 16 | 32 | 48 |
| 2021 11 | 24 | 46 | 70 |
| 2021 10 | 25 | 38 | 63 |
| 2021 9 | 21 | 33 | 54 |
| 2021 8 | 15 | 20 | 35 |
| 2021 7 | 17 | 26 | 43 |
| 2021 6 | 6 | 28 | 34 |
| 2021 5 | 18 | 26 | 44 |
| 2021 4 | 22 | 32 | 54 |
| 2021 3 | 36 | 16 | 52 |
| 2021 2 | 12 | 9 | 21 |
| 2020 1 | 8 | 9 | 17 |
| 2020 12 | 16 | 9 | 25 |
| 2020 11 | 12 | 9 | 21 |
| 2020 10 | 7 | 9 | 16 |
| 2020 9 | 7 | 6 | 13 |
| 2020 8 | 10 | 9 | 19 |
| 2020 7 | 15 | 12 | 27 |
| 2020 6 | 15 | 10 | 25 |
| 2020 5 | 31 | 10 | 41 |
| 2020 4 | 45 | 14 | 59 |
| 2020 3 | 17 | 11 | 28 |
| 2020 2 | 51 | 13 | 64 |
| 2020 1 | 11 | 11 | 22 |
| 2019 12 | 13 | 9 | 22 |
| 2019 11 | 12 | 4 | 16 |
| 2019 10 | 8 | 6 | 14 |
| 2019 9 | 11 | 4 | 15 |
| 2019 8 | 10 | 7 | 17 |
| 2019 7 | 10 | 6 | 16 |
| 2019 6 | 7 | 8 | 15 |
| 2019 5 | 9 | 11 | 20 |
| 2019 4 | 13 | 7 | 20 |
| 2019 3 | 16 | 8 | 24 |
| 2019 2 | 18 | 10 | 28 |
| 2019 1 | 7 | 5 | 12 |
| 2018 12 | 6 | 5 | 11 |
| 2018 11 | 23 | 16 | 39 |
| 2018 10 | 35 | 23 | 58 |
| 2018 9 | 17 | 11 | 28 |
| 2018 8 | 8 | 8 | 16 |
| 2018 7 | 21 | 6 | 27 |
| 2018 6 | 20 | 8 | 28 |
| 2018 5 | 14 | 10 | 24 |
| 2018 4 | 7 | 5 | 12 |
| 2018 3 | 12 | 4 | 16 |
| 2018 2 | 11 | 5 | 16 |
| 2018 1 | 4 | 3 | 7 |
| 2017 12 | 9 | 10 | 19 |
| 2017 11 | 12 | 11 | 23 |
| 2017 10 | 11 | 7 | 18 |
| 2017 9 | 16 | 11 | 27 |
| 2017 8 | 15 | 14 | 29 |
| 2017 7 | 15 | 14 | 29 |
| 2017 6 | 27 | 10 | 37 |
| 2017 5 | 27 | 4 | 31 |
| 2017 4 | 16 | 9 | 25 |
| 2017 3 | 22 | 4 | 26 |
| 2017 2 | 10 | 4 | 14 |
| 2016 1 | 13 | 4 | 17 |
| 2016 12 | 18 | 4 | 22 |
| 2016 11 | 21 | 8 | 29 |
| 2016 10 | 25 | 13 | 38 |
| 2016 9 | 28 | 4 | 32 |
| 2016 8 | 30 | 9 | 39 |
| 2016 7 | 17 | 8 | 25 |
| 2016 4 | 1 | 0 | 1 |
| 2016 2 | 1 | 0 | 1 |
| 2015 12 | 1 | 0 | 1 |
| 2015 9 | 1 | 0 | 1 |
| 2015 6 | 1 | 0 | 1 |
| 2015 4 | 2 | 0 | 2 |
| 2015 3 | 1 | 0 | 1 |
| 2015 1 | 2 | 0 | 2 |
| 2014 12 | 5 | 0 | 5 |
| 2014 11 | 3 | 0 | 3 |
| 2014 10 | 3 | 0 | 3 |
| 2014 9 | 3 | 0 | 3 |
| 2014 8 | 13 | 0 | 13 |
| 2014 7 | 10 | 0 | 10 |
| 2014 6 | 10 | 0 | 10 |
| 2014 5 | 5 | 0 | 5 |
| 2014 4 | 7 | 0 | 7 |
| 2014 3 | 5 | 0 | 5 |
| 2014 2 | 4 | 1 | 5 |
| 2014 1 | 9 | 1 | 10 |
| 2013 12 | 17 | 1 | 18 |
| 2013 11 | 20 | 2 | 22 |
| 2013 10 | 21 | 3 | 24 |
| 2013 9 | 13 | 2 | 15 |
| 2013 8 | 23 | 1 | 24 |
| 2013 7 | 22 | 1 | 23 |
| 2003 6 | 1334 | 0 | 1334 |
Mostrar todo
